<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is a <z:e sem="disease" ids="C0282313" disease_type="Neoplastic Process" abbrv="">preneoplastic condition</z:e> that frequently develops into overt <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The P39 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell line manifested constitutive NF-kappaB activation </plain></SENT>
<SENT sid="2" pm="."><plain>In this cell line, NF-kappaB inhibition by small interfering <z:chebi fb="40" ids="33697">RNAs</z:chebi> specific for p65 or chemical inhibitors including <z:chebi fb="0" ids="52717">bortezomib</z:chebi> resulted in the down-regulation of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inhibitory NF-kappaB target genes and subsequent cell <z:hpo ids='HP_0011420'>death</z:hpo> accompanied by loss of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> transmembrane potential as well as by the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> release of the caspase activator <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> and the caspase-independent <z:hpo ids='HP_0011420'>death</z:hpo> effectors endonuclease G and <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing factor (AIF) </plain></SENT>
<SENT sid="3" pm="."><plain>Bone marrow cells from high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients also exhibited constitutive NF-kappaB activation similar to bone marrow samples from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Purified hematopoietic stem cells (CD34+) and immature myeloid cells (CD33+) from high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients demonstrated the nuclear translocation of the p65 NF-kappaB subunit </plain></SENT>
<SENT sid="5" pm="."><plain>The frequency of cells with nuclear p65 correlated with blast counts, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> suppression, and disease progression </plain></SENT>
<SENT sid="6" pm="."><plain>NF-kappaB activation was confined to those cells that carried <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-associated cytogenetic alterations </plain></SENT>
<SENT sid="7" pm="."><plain>Since NF-kappaB inhibition induced rapid <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of bone marrow cells from high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, we postulate that NF-kappaB activation is responsible for the progressive suppression of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> affecting differentiating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells and thus contributes to <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>NF-kappaB inhibition may constitute a novel therapeutic strategy if <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> stem cells is the goal </plain></SENT>
</text></document>